Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.

Jenkins, P Vincent, Bowyer, Annette, Burgess, Clive, Gray, Elaine, Kitchen, Steve, Murphy, Paul, Platton, Sean, Riddell, Anne, Chowdary, Pratima and Lester, Will (2019) Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia : the official journal of the World Federation of Hemophilia. ISSN 1365-2516. This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/

Full text not available from this repository.
Official URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/ha...

Abstract

INTRODUCTION

The factor VIII mimetic emicizumab (Hemlibra, Hoffman-la Roche, Basel, Switzerland) has a novel mode of action that affects the laboratory monitoring of patients receiving this treatment.

AIM

This guideline from the United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO) aims to provide advice for clinical and laboratory staff on appropriate use of laboratory assays in patients with Haemophilia A treated with emicizumab.

METHODOLOGY

The guideline was prepared by a review of the available literature and discussion and revision by the authors.

RESULTS

The guideline describes the effect of emicizumab on commonly used coagulations tests and provides recommendations on the use of assays for measurement of factor VIII and factor VIII inhibitor in the presence of emicizumab. The guideline also provides recommendations on measurement of emicizumab.

CONCLUSION

Knowledge of the effect of emicizumab on coagulation tests and factor assays is required to ensure appropriate testing and monitoring of therapy in patients receiving this drug.

Item Type: Article
Additional Information: This article is available to all UHB staff and students login using a UHB Athens Account. Register for Athens here - https://openathens.nice.org.uk/
Subjects: WH Haemic and lymphatic systems. Haematology
Divisions: Planned IP Care > Oncology and Clinical Haematology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 02 Jan 2020 13:57
Last Modified: 05 May 2022 07:25
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2727

Actions (login required)

View Item View Item